Research ArticleBasic Science Investigations
Quantitative PET of Human Urokinase-Type Plasminogen Activator Receptor with 64Cu-DOTA-AE105: Implications for Visualizing Cancer Invasion
Morten Persson, Jacob Madsen, Søren Østergaard, Mette Munk Jensen, Jesper Tranekjær Jørgensen, Karina Juhl, Charlotte Lehmann, Michael Ploug and Andreas Kjaer
Journal of Nuclear Medicine January 2012, 53 (1) 138-145; DOI: https://doi.org/10.2967/jnumed.110.083386
Morten Persson
Jacob Madsen
Søren Østergaard
Mette Munk Jensen
Jesper Tranekjær Jørgensen
Karina Juhl
Charlotte Lehmann
Michael Ploug
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 53, Issue 1
January 1, 2012
Quantitative PET of Human Urokinase-Type Plasminogen Activator Receptor with 64Cu-DOTA-AE105: Implications for Visualizing Cancer Invasion
Morten Persson, Jacob Madsen, Søren Østergaard, Mette Munk Jensen, Jesper Tranekjær Jørgensen, Karina Juhl, Charlotte Lehmann, Michael Ploug, Andreas Kjaer
Journal of Nuclear Medicine Jan 2012, 53 (1) 138-145; DOI: 10.2967/jnumed.110.083386
Quantitative PET of Human Urokinase-Type Plasminogen Activator Receptor with 64Cu-DOTA-AE105: Implications for Visualizing Cancer Invasion
Morten Persson, Jacob Madsen, Søren Østergaard, Mette Munk Jensen, Jesper Tranekjær Jørgensen, Karina Juhl, Charlotte Lehmann, Michael Ploug, Andreas Kjaer
Journal of Nuclear Medicine Jan 2012, 53 (1) 138-145; DOI: 10.2967/jnumed.110.083386
Jump to section
Related Articles
Cited By...
- Prognostic Value of Urokinase-Type Plasminogen Activator Receptor PET/CT in Head and Neck Squamous Cell Carcinomas and Comparison with 18F-FDG PET/CT: A Single-Center Prospective Study
- Urokinase-Type Plasminogen Activator Receptor (uPAR) PET/MRI of Prostate Cancer for Noninvasive Evaluation of Aggressiveness: Comparison with Gleason Score in a Prospective Phase 2 Clinical Trial
- Safety, Dosimetry, and Tumor Detection Ability of 68Ga-NOTA-AE105: First-in-Human Study of a Novel Radioligand for uPAR PET Imaging
- Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma
- uPAR as a Glioma Imaging Target
- Interrogating Tumor Metabolism and Tumor Microenvironments Using Molecular Positron Emission Tomography Imaging. Theranostic Approaches to Improve Therapeutics
- A Flexible Multidomain Structure Drives the Function of the Urokinase-type Plasminogen Activator Receptor (uPAR)